The progress in medical treatments loses a lot of its value when patients cannot get rid of them within a short period of … Discover it, this happens in Spain with cancer treatments. Tumor medicine takes two years by the national health system (SNS) after it is positively estimated by the European Pharmaceutical Agency (EMA), according to the Spanish Society for Cancer Research (ASEICA).
The average time has increased since it has received an anti -tumor vehicle green light for EMA until it gets approval to pay SNS from 395 days in 2018 to 721 in 2023.
The process of financing medicine in Spain highlights its complexity. First, the pharmacist must submit a marketing application to the Spanish Agency for Medicines and Health Products (AEMPS). After that, the drug is included in negotiating prices and financing through the General Directorate of the Joint Portfolio of Services for the Health System and National Pharmacy and the intertwined negotiations of prices for medicines and health products (CIMP), a member in which the Ministry of Health, Industry, Economy and Independent Communities participate. Later, you can go to the SNS Services wallet, but there may also be other delays, since societies and even hospitals can open new negotiations.
The delay in the passage of medicines is compensated for medicines, in some way, due to the fact that Spain is the first European country in clinical trials, which allow patients to reach the drugs, even if they are in the test stage. But between professionals and among patients, the drugs are seen as a major problem “that can include loss of treatment opportunities, the development of the disease or less survival,” says Sotangas.
“Spain’s capabilities as a pioneer in clinical experiences in effective and fair access to vehicles and new technologies should be reflected,” added Dr. Rafael Lopez, head of Aseica, who asks about “a continuous investment in basic and real research.”
Researchers suggest some measures to improve access to new treatments: increased investment in research and data collection; Ensuring compliance with legal deadlines; AgPination in decision -making, more transparency and more coordination between health authorities and industry; Homoing access to innovation throughout the country through a central fund; Implementing systems such as pushing periodic results and reviews to integrate new treatments; And enhance the participation of greater patients and professionals.
